凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
梅花生物(600873)公告正文

梅花生物:2015年第三季度报告

公告日期 2015-10-27
股票简称:梅花生物 股票代码:600873
                        2015 年第三季度报告



公司代码:600873                              公司简称:梅花生物




            梅花生物科技集团股份有限公司

                   2015 年第三季度报告




                              1 / 21
                             2015 年第三季度报告




                                目录
一、重要提示............................................................ 3

二、公司主要财务数据和股东变化.......................................... 3

三、重要事项............................................................ 6

四、附录............................................................... 10




                                   2 / 21
                                      2015 年第三季度报告




一、 重要提示


1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,

    不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。

1.2 公司全体董事出席董事会审议季度报告。

1.3 公司负责人孟庆山、主管会计工作负责人李勇刚及会计机构负责人(会计主管人员)王爱玲

    保证季度报告中财务报表的真实、准确、完整。

1.4 本公司第三季度报告未经审计。


二、 公司主要财务数据和股东变化


2.1 主要财务数据
                                                                             单位:元    币种:人民币
                                                                             本报告期末比上年度末增
                               本报告期末                 上年度末
                                                                                         减(%)
          总资产             18,645,139,070.68          20,601,673,245.05                         -9.50
归属于上市公司股东的净资产    8,284,875,698.77           8,216,552,097.35                         0.83
                             年初至报告期末         上年初至上年报告期末
                                                                                比上年同期增减(%)
                                (1-9 月)               (1-9 月)
经营活动产生的现金流量净额    2,562,811,209.88              551,436,190.63                       364.75
                             年初至报告期末         上年初至上年报告期末         比上年同期增减
                                (1-9 月)               (1-9 月)                      (%)
         营业收入             8,819,890,851.38           7,276,815,615.07                         21.21
归属于上市公司股东的净利润      383,528,008.72              271,257,797.78                        41.39
归属于上市公司股东的扣除非
                                274,632,032.44              189,326,996.50                        45.06
    经常性损益的净利润
 加权平均净资产收益率(%)                   4.66                     3.39         增加 1.27 个百分点
   基本每股收益(元/股)                     0.12                     0.09                        33.33
   稀释每股收益(元/股)                     0.12                     0.09                        33.33




非经常性损益项目和金额
√适用 □不适用
                                                                              单位:元    币种:人民币
                               本期金额             年初至报告期末金额                  说明
          项目
                              (7-9 月)               (1-9 月)
非流动资产处置损益                 -671,804.71               -866,706.77
越权审批,或无正式批准文
                                               3 / 21
                                2015 年第三季度报告



件,或偶发性的税收返还、
减免
计入当期损益的政府补助,
但与公司正常经营业务密切
相关,符合国家政策规定、   39,489,369.45          81,318,924.95
按照一定标准定额或定量持
续享受的政府补助除外
计入当期损益的对非金融企
业收取的资金占用费
企业取得子公司、联营企业
及合营企业的投资成本小于
取得投资时应享有被投资单
位可辨认净资产公允价值产
生的收益
非货币性资产交换损益
委托他人投资或管理资产的
                                                  24,739,726.03
损益
因不可抗力因素,如遭受自
然灾害而计提的各项资产减
值准备
债务重组损益
企业重组费用,如安置职工
的支出、整合费用等
交易价格显失公允的交易产
生的超过公允价值部分的损

同一控制下企业合并产生的
子公司期初至合并日的当期
净损益
与公司正常经营业务无关的
或有事项产生的损益
除同公司正常经营业务相关
的有效套期保值业务外,持
有交易性金融资产、交易性
金融负债产生的公允价值变
                            2,870,456.60              6,528,932.79
动损益,以及处置交易性金
融资产、交易性金融负债和
可供出售金融资产取得的投
资收益
单独进行减值测试的应收款
项减值准备转回
对外委托贷款取得的损益
采用公允价值模式进行后续


                                      4 / 21
                                           2015 年第三季度报告



计量的投资性房地产公允价
值变动产生的损益
根据税收、会计等法律、法
规的要求对当期损益进行一
次性调整对当期损益的影响
受托经营取得的托管费收入
除上述各项之外的其他营业
                                     3,514,415.27                7,576,795.79
外收入和支出
其他符合非经常性损益定义
的损益项目
所得税影响额                        -4,436,767.15             -10,316,044.90
少数股东权益影响额(税后)             -66,681.01                  -85,651.61
           合计                     40,698,988.45             108,895,976.28


2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表
                                                                                                 单位:股
股东总数(户)                                                                                      249,459
                                           前十名股东持股情况
   股东名称        期末持股数    比例(%)    持有有限售条件           质押或冻结情况              股东性质
   (全称)            量                      股份数量          股份状态           数量
孟庆山             854,103,033     27.48                  0        质押         380,240,000   境内自然人
胡继军             248,469,341      7.99                  0         无                        境内自然人
中国证券金融股
                    89,548,948      2.88                  0        未知                            未知
份有限公司
杨维永              78,810,526      2.54                  0         无                        境内自然人
王爱军              71,316,274      2.29                  0         无                        境内自然人
梁宇博              53,668,518      1.73                  0         无                        境内自然人
全国社保基金一
                    47,999,734      1.54                  0        未知                            未知
零二组合
中国人寿保险股
份有限公司-分
                    40,884,098      1.32                  0        未知                            未知
红-个人分红-
005L-FH002 沪
香港鼎晖生物科
                    40,125,120      1.29                  0        未知                          境外法人
技有限公司
全国社保基金一
                    26,611,453      0.86                  0        未知                            未知
一八组合
                                    前十名无限售条件股东持股情况
股东名称                         持有无限售条件流通股的数量                     股份种类及数量
                                                                             种类                数量
孟庆山                                              854,103,033          人民币普通股         854,103,033
胡继军                                              24,8469,341          人民币普通股         248,469,341
中国证券金融股份有限公司                             89,548,948          人民币普通股            89,548,948
                                                 5 / 21
                                           2015 年第三季度报告



杨维永                                                78,810,526       人民币普通股            78,810,526
王爱军                                                71,316,274       人民币普通股            71,316,274
梁宇博                                                53,668,518       人民币普通股            53,668,518
全国社保基金一零二组合                                47,999,734       人民币普通股            47,999,734
中国人寿保险股份有限公司-
分红-个人分红-005L-FH002                           40,884,098       人民币普通股            40,884,098

香港鼎晖生物科技有限公司                              40,125,120       人民币普通股            40,125,120
全国社保基金一一八组合                                26,611,453       人民币普通股            26,611,453
上述股东关联关系或一致行动
                                   孟庆山、杨维永、王爱军为一致行动人,其他股东未知其一致行动关系。
的说明
     注:孟庆山、杨维永、王爱军等出具承诺:其持有的公司股份自 2014 年 1 月 2 日上市流通之日起追加限售锁
定期 24 个月,即自 2014 年 1 月 2 日起 24 个月不上市交易或转让,限售期满后按照中国证监会或上海证券交易所
的有关规定执行。

2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股情
     况表

□适用 √不适用


三、 重要事项


3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
√适用 □不适用
资产负债表项目:
                                                                                              单位:万元
           项目            本报告期末    上年度期末     增减额      增减幅度%             差异说明
交易性金融资产               13,360.00                 13,360.00       100.00    本期购买理财产品
应收票据                      4,788.41     8,143.58     -3,355.17       -41.20   本期承兑付款增加所致
                                                                                 主要为本公司之子公司新疆梅
预付款项                     67,567.44   118,905.84    -51,338.40       -43.18   花氨基酸有限责任公司预付玉
                                                                                 米款减少所致
                                                                                 本公司子公司通辽梅花生物科
其他流动资产                 27,173.81    47,308.69    -20,134.88       -42.56   技有限公司期末预交税款减少
                                                                                 所致
                                                                                 本期本公司之子公司新疆梅花
在建工程                     31,888.84   104,235.19    -72,346.35       -69.41   氨基酸有限责任公司部分项目
                                                                                 转固所致
研发支出                         67.50                     67.50       100.00    本期新增研发项目所致
                                                                                 主要系存货内部交易未实现利
递延所得税资产                 716.39      2,855.17     -2,138.78       -74.91   润影响递延所得税资产减少所
                                                                                 致
                                                                                 本期收回原委托渤海国际信托
其他非流动资产                            23,002.15    -23,002.15      -100.00
                                                                                 有限公司进行投资的款项
短期借款                    239,893.05   501,176.95   -261,283.90       -52.13   本期偿还到期借款所致


                                                  6 / 21
                                                 2015 年第三季度报告



应付票据                                         4,300.00       -4,300.00           -100.00         本期票据到期承付所致
                                                                                                    主要系本期归还股东借款及归
其他应付款                     49,877.67        83,307.62      -33,429.95               -40.13
                                                                                                    还通辽财政局借款所致
                                                                                                    本期编号为 12 梅花 MTN1 中期
                                                                                                    票据及 14 梅花 CP001、14 梅花
一年内到期的非流动负债      129,834.50       390,509.57       -260,675.07               -66.75
                                                                                                    CP002 两期短期融资劵已到期
                                                                                                    偿还所致
其他流动负债                194,880.83                         194,880.83               100.00      本期发行超短期融资券所致
                                                                                                    本期将一年内到期长期借款重
长期借款                       54,338.00        85,336.11      -30,998.11               -36.32      分类至一年内到期非流动负债
                                                                                                    所致
                                                                                                    本期公开发行 15 亿公司债券
应付债券                    149,114.96                         149,114.96               100.00
                                                                                                    所致
长期应付款                     38,041.65                        38,041.65               100.00      本期融资租赁业务增加所致

利润表项目:
                                                                                                                  单位:万元
     项目           本报告期        上年同期          增减额            增减幅度%                          差异说明
营业税金及附加        3,778.26        1,873.56          1,904.70               101.66     本期流转税增加所致
                                                                                          主要系本期员工工资费用增加,以
   管理费用          38,466.02       28,378.33         10,087.69                35.55
                                                                                          及折旧摊销费用增加所致
 资产减值损失          -498.31          725.76         -1,224.07            -168.66       本期转回坏账准备所致
                                                                                          原委托渤海国际信托有限公司进行
   投资收益           2,848.63          322.36          2,526.27               783.68
                                                                                          投资的投资收益收回所致
  营业外支出             340.70         833.68              -492.98            -59.13     本期固定资产处置损失减少所致
                                                                                          本期利润增加导致计提所得税费用
  所得税费用         10,295.45        3,701.28          6,594.17               178.16
                                                                                          增加
                                                                                          本期子公司新疆梅花产能继续释
                                                                                          放,销量增加,同时氨基酸市场、
                                                                                          味精市场逐步复苏,公司主要产品
    净利润           40,030.13       27,125.78         12,904.35                47.57
                                                                                          味精、赖氨酸、苏氨酸等销售价格
                                                                                          上涨带来利润的增加,以及本期理
                                                                                          财收益增加所致。

现金流量表项目:
                                                                                                                  单位:万元
             项目                 本报告期        上年同期            增减额       增减幅度%                   差异说明
                                                                                                      主要系本期销售货款增加
经营活动产生的现金流量净额        256,281.12      55,143.62      201,137.50              -364.75
                                                                                                      所致
                                                                                                      主要系本期收回委托理财
投资活动产生的现金流量净额         -30,224.38    -66,379.70           36,155.32            54.47      资金及取得收益,以及对
                                                                                                      外投资支付资金减少所致
                                                                                                      主要系本期偿还到期债务
筹资活动产生的现金流量净额        -268,023.52     26,744.86      -294,768.37            -1,102.15
                                                                                                      资金支出增加所致




                                                        7 / 21
                                       2015 年第三季度报告




3.2 重要事项进展情况及其影响和解决方案的分析说明
√适用 □不适用
    (1)终止发行股份购买资产事宜
    公司拟向铁小荣及宁夏伊品投资集团有限公司等 9 家企业发行股份及支付现金 70,000 万元购
买宁夏伊品生物科技股份有限公司 100%权益。该事项已经公司第七届董事会第十一次会议及 2015
年第一次临时股东大会审议通过。具体内容详见公司前期临时公告及定期报告。
    鉴于前述交易存在的不确定事项和并购整合风险,公司综合考虑各种风险因素,从保护全体
股东利益及维护市场稳定出发,决定终止本次发行股份及支付现金购买资产并配套募集资金事项,
该事项已经公司第七届董事会第二十次会议和 2015 年第三次临时股东大会审议通过,公司已于
2015 年 9 月 1 日召开了投资者说明会,会上就投资者关注的相关问题进行了答复。同时,公司承
诺在披露投资者说明会召开情况公告后的 3 个月内,不再筹划重大资产重组事项。
    (2)公司债券发行情况
    2015 年 7 月 29 日,公司发行了 2015 年公司债券(第一期),发行面值不超过 15 亿元人民
币公司债券(含不超过 5 亿元超额配售额度),发行价格为 100 元/张。本次债券发行工作已于
2015 年 8 月 4 日结束,实际发行规模为 15 亿元,最终票面利率为 4.47%,募集总额为 15 亿元人
民币,扣除 900 万元承销费,实际到账金额为 149,100 万元,资金到账日期为 2015 年 8 月 5 日。
    (3)员工持股计划的进展情况
    经公司第七届董事会第十八次会议和公司 2015 年第二次临时股东大会审议通过,公司计划在
适当的时机开展员工持股计划。员工持股计划筹集资金总额上限为 36000 万元,参与对象认购员
工持股计划的资金来源为其合法薪酬及法律法规允许的其他方式。
    截止本报告出具日,员工持股计划专户尚未买入相关股票。



3.3 公司及持股 5%以上的股东承诺事项履行情况
√适用 □不适用



承诺   承诺类     承诺                                        承诺时间及     是否有履行   是否及时
                                     承诺内容
背景     型         方                                            期限           期限     严格履行


                         在重组完成后,孟庆山先生及一致行动
                         人将尽量避免与上市公司的关联交易,
与重
                  孟庆   若有不可避免的关联交易,孟庆山先生
大资
                  山及   及一致行动人与上市公司将依法签订     2010 年 7 月
产重   解决关
                  其一   协议,履行合法程序,并将按照有关法   19 日出具承        否          是
组相   联交易
                  致行   律、法规、《公司章程》等有关规定履        诺
关的
                  动人   行信息披露义务和办理有关报批事宜。
承诺
                         保证不通过关联交易损害上市公司及
                                 其他股东的合法权益。

                                             8 / 21
                                         2015 年第三季度报告


与重
                  孟庆
大资                     在本次交易完成后继续保持上市公司
                  山及                                             2010 年 7 月
产重                     的独立性,在资产、人员、财务、机构、
        其他      其一                                             19 日出具承        否        是
组相                     业务上遵循五分开原则,遵守中国证监
                  致行                                                  诺
关的                       会有关规定,规范运作上市公司。
                  动人
承诺
                         在孟庆山先生及一致行动人作为上市
与重
                  孟庆   公司控股股东或实际控制人之期限内,
大资
                  山及   将采取有效措施,并促使孟庆山先生或        2010 年 7 月
产重   解决同
                  其一   孟庆山先生及一致行动人下属控股子          19 日出具承        否        是
组相   业竞争
                  致行   公司采取有效措施,不会从事或参与任             诺
关的
                  动人   何可能对上市公司或其控股子公司目
承诺
                         前主要从事的业务构成竞争的业务。
                股东
                孟庆      上述五人持有的公司股份自 2014 年 1
                山、杨   月 2 日上市流通之日起追加限售锁定期       24 个月,2014
其他   股份限   维永、   24 个月,即自 2014 年 1 月 2 日起 24 个    年1月2日
                                                                                      是        是
承诺     售     王爱     月不上市交易或转让,限售期满后按照        -2016 年 1 月
                军、何    中国证监会或上海证券交易所的有关              2日
                君、杨                规定执行。
                维英




3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警

    示及原因说明
□适用 √不适用




                                                     公司名称          梅花生物科技集团股份有限公司


                                                   法定代表人                       孟庆山


                                                       日期                        2015-10-26




                                                 9 / 21
                                       2015 年第三季度报告




四、 附录


4.1 财务报表
                                    合并资产负债表
                                   2015 年 9 月 30 日
编制单位:梅花生物科技集团股份有限公司

                                                           单位:元   币种:人民币   审计类型:未经审计
                     项目                              期末余额                      年初余额
流动资产:
  货币资金                                              1,233,718,375.63             1,410,780,531.53
  结算备付金
  拆出资金
  以公允价值计量且其变动计入当期损益的金
                                                          133,600,000.00
融资产
  衍生金融资产
  应收票据                                                 47,884,061.78                81,435,784.69
  应收账款                                                427,118,330.58               384,090,179.14
  预付款项                                                675,674,357.46             1,189,058,406.22
  应收保费
  应收分保账款
  应收分保合同准备金
  应收利息
  应收股利
  其他应收款                                              474,969,911.26               505,727,015.91
  买入返售金融资产
  存货                                                  1,592,140,453.87             1,917,060,383.40
  划分为持有待售的资产
  一年内到期的非流动资产
  其他流动资产                                            271,738,080.84               473,086,939.60
    流动资产合计                                        4,856,843,571.42             5,961,239,240.49
非流动资产:
  发放贷款及垫款
  可供出售金融资产                                        191,000,000.00               157,000,000.00
  持有至到期投资
  长期应收款
  长期股权投资                                             73,833,324.43                76,615,704.68
  投资性房地产
  固定资产                                             11,866,076,528.45            11,797,980,303.72
  在建工程                                                318,888,362.35             1,042,351,913.38
  工程物资                                                  6,973,673.21                 8,887,733.74

                                             10 / 21
                                       2015 年第三季度报告



  固定资产清理
  生产性生物资产
  油气资产
  无形资产                                                890,160,173.78      865,500,541.28
  开发支出                                                    675,000.00
  商誉                                                    433,524,530.32      433,524,530.32
  长期待摊费用
  递延所得税资产                                            7,163,906.72       28,551,732.16
  其他非流动资产                                                              230,021,545.28
    非流动资产合计                                     13,788,295,499.26   14,640,434,004.56
      资产总计                                         18,645,139,070.68   20,601,673,245.05
流动负债:
  短期借款                                              2,398,930,543.35    5,011,769,533.28
  向中央银行借款
  吸收存款及同业存放
  拆入资金
  以公允价值计量且其变动计入当期损益的金
融负债
  衍生金融负债
  应付票据                                                                     43,000,000.00
  应付账款                                                910,103,003.29      867,949,855.60
  预收款项                                                312,471,087.15      372,200,472.73
  卖出回购金融资产款
  应付手续费及佣金
  应付职工薪酬                                             73,038,927.43       59,444,446.79
  应交税费                                                 37,465,631.92       46,019,214.45
  应付利息                                                150,452,546.62      139,428,338.31
  应付股利
  其他应付款                                              498,776,696.01      833,076,221.63
  应付分保账款
  保险合同准备金
  代理买卖证券款
  代理承销证券款
  划分为持有待售的负债
  一年内到期的非流动负债                                1,298,344,970.00    3,905,095,662.44
  其他流动负债                                          1,948,808,333.35
    流动负债合计                                        7,628,391,739.12   11,277,983,745.23
非流动负债:
  长期借款                                                543,380,000.00      853,361,100.00
  应付债券                                              1,491,149,629.89
  其中:优先股
         永续债

                                             11 / 21
                                         2015 年第三季度报告



  长期应付款                                                380,416,538.84
  长期应付职工薪酬
  专项应付款
  预计负债
  递延收益                                                   66,050,969.49                  65,577,951.03
  递延所得税负债                                             21,528,703.21                  22,734,163.18
  其他非流动负债
    非流动负债合计                                        2,502,525,841.43                 941,673,214.21
      负债合计                                           10,130,917,580.55            12,219,656,959.44
所有者权益
  股本                                                    3,108,226,603.00               3,108,226,603.00
  其他权益工具
  其中:优先股
         永续债
  资本公积                                                2,240,464,636.21               2,240,485,918.58
  减:库存股
  其他综合收益
  专项储备
  盈余公积                                                  224,074,848.34                 224,074,848.34
  一般风险准备
  未分配利润                                              2,712,109,611.22               2,643,764,727.43
  归属于母公司所有者权益合计                              8,284,875,698.77               8,216,552,097.35
  少数股东权益                                              229,345,791.36                 165,464,188.26
    所有者权益合计                                        8,514,221,490.13               8,382,016,285.61
      负债和所有者权益总计                               18,645,139,070.68            20,601,673,245.05
法定代表人:孟庆山          主管会计工作负责人:李勇刚          会计机构负责人:王爱玲


                                   母公司资产负债表
                                   2015 年 9 月 30 日
编制单位:梅花生物科技集团股份有限公司
                                                              单位:元   币种:人民币   审计类型:未经审计
                     项目                                期末余额                     年初余额
流动资产:
  货币资金                                                 382,825,732.01                  325,483,860.79
  以公允价值计量且其变动计入当期损益的金                   117,700,000.00
融资产
  衍生金融资产
  应收票据                                                  22,928,459.14                   17,151,070.98
  应收账款                                                 236,708,888.46                  180,327,599.35
  预付款项                                                   5,775,395.10                  809,763,519.50
  应收利息
  应收股利                                                                                 300,000,000.00

                                               12 / 21
                                       2015 年第三季度报告



  其他应收款                                            5,072,820,739.77    7,038,656,760.20
  存货                                                     72,005,054.51      429,976,073.97
  划分为持有待售的资产
  一年内到期的非流动资产
  其他流动资产                                             14,842,720.65       51,402,539.65
    流动资产合计                                        5,925,606,989.64    9,152,761,424.44
非流动资产:
  可供出售金融资产                                        157,000,000.00      157,000,000.00
  持有至到期投资
  长期应收款                                            1,511,654,087.44
  长期股权投资                                          5,411,833,324.43    5,414,615,704.68
  投资性房地产
  固定资产                                                198,560,610.57      212,086,216.37
  在建工程
  工程物资
  固定资产清理
  生产性生物资产
  油气资产
  无形资产                                                 67,181,393.44       42,751,078.98
  开发支出
  商誉
  长期待摊费用
  递延所得税资产                                              871,586.64        1,681,310.17
  其他非流动资产                                                              200,000,000.00
    非流动资产合计                                      7,347,101,002.52    6,028,134,310.20
      资产总计                                         13,272,707,992.16   15,180,895,734.64
流动负债:
  短期借款                                                700,000,000.00    2,115,000,000.00
  以公允价值计量且其变动计入当期损益的金
融负债
  衍生金融负债
  应付票据                                                130,000,000.00       43,000,000.00
  应付账款                                                603,104,535.74    1,953,965,038.69
  预收款项                                                203,600,539.38      287,516,184.57
  应付职工薪酬                                              3,804,453.65        3,777,892.97
  应交税费                                                  1,169,945.54       13,367,869.02
  应付利息                                                129,443,766.53      129,562,019.97
  应付股利
  其他应付款                                              831,852,606.14      178,521,639.91
  划分为持有待售的负债
  一年内到期的非流动负债                                1,000,000,000.00    3,895,095,662.44
  其他流动负债                                          1,948,808,333.35

                                             13 / 21
                                           2015 年第三季度报告



    流动负债合计                                            5,551,784,180.33               8,619,806,307.57
非流动负债:
  长期借款                                                    400,000,000.00                 400,000,000.00
  应付债券                                                  1,491,149,629.89
  其中:优先股
         永续债
  长期应付款
  长期应付职工薪酬
  专项应付款
  预计负债
  递延收益
  递延所得税负债
  其他非流动负债
    非流动负债合计                                          1,891,149,629.89                 400,000,000.00
      负债合计                                              7,442,933,810.22               9,019,806,307.57
所有者权益:
  股本                                                      3,108,226,603.00               3,108,226,603.00
  其他权益工具
  其中:优先股
         永续债
  资本公积                                                  2,208,701,622.94               2,208,701,622.94
  减:库存股
  其他综合收益
  专项储备
  盈余公积                                                    224,074,848.34                 224,074,848.34
  未分配利润                                                  288,771,107.66                 620,086,352.79
    所有者权益合计                                          5,829,774,181.94               6,161,089,427.07
      负债和所有者权益总计                                 13,272,707,992.16             15,180,895,734.64


法定代表人:孟庆山        主管会计工作负责人:李勇刚              会计机构负责人:王爱玲


                                               合并利润表
                                             2015 年 1—9 月
编制单位:梅花生物科技集团股份有限公司
                                                               单位:元    币种:人民币   审计类型:未经审计
                                                                          年初至报告期     上年年初至报告
                                本期金额            上期金额
             项目                                                     期末金额 (1-9       期期末金额(1-9
                                (7-9 月)          (7-9 月)
                                                                              月)              月)
一、营业总收入               2,660,467,101.39   2,665,157,895.18     8,819,890,851.38      7,276,815,615.07
其中:营业收入               2,660,467,101.39   2,665,157,895.18     8,819,890,851.38      7,276,815,615.07
      利息收入
      已赚保费

                                                 14 / 21
                                         2015 年第三季度报告



       手续费及佣金收入
二、营业总成本               2,635,988,804.70   2,543,283,555.02    8,433,150,366.05   7,059,332,009.26
其中:营业成本               2,145,617,494.23   2,153,686,674.26    7,015,375,895.37   5,944,021,810.21
       利息支出
       手续费及佣金支出
       退保金
       赔付支出净额
       提取保险合同准备金
净额
       保单红利支出
       分保费用
       营业税金及附加           8,724,000.46        6,437,475.74       37,782,568.63      18,735,585.46
       销售费用               189,577,685.99      170,804,677.34      620,423,291.90     486,100,054.36
       管理费用               150,145,169.80      102,744,200.21      384,660,169.34     283,783,283.30
       财务费用               141,758,620.47      109,610,637.47      379,891,530.43     319,433,666.54
       资产减值损失               165,833.75              -110.00      -4,983,089.62       7,257,609.39
  加:公允价值变动收益(损
失以“-”号填列)
       投资收益(损失以
                                4,108,479.19         -603,286.02       28,486,278.57       3,223,585.71
“-”号填列)
       其中:对联营企业和
                                1,238,022.59       -1,614,502.55       -2,782,380.25        -957,300.88
合营企业的投资收益
       汇兑收益(损失以
“-”号填列)
三、营业利润(亏损以“-”
                               28,586,775.88      121,271,054.14      415,226,763.90     220,707,191.52
号填列)
  加:营业外收入               44,172,827.61       28,857,656.22       91,436,055.96      95,900,222.54
       其中:非流动资产处
                                     4,784.90          11,854.82           30,151.71          91,646.34
置利得
  减:营业外支出                1,840,847.60        2,401,185.62        3,407,041.99       8,336,794.58
       其中:非流动资产处
                                  676,589.61        2,357,350.58          896,858.48       7,916,131.60
置损失
四、利润总额(亏损总额以
                               70,918,755.89      147,727,524.74      503,255,777.87     308,270,619.48
“-”号填列)
  减:所得税费用               19,925,844.47        8,878,257.11      102,954,462.25      37,012,821.70
五、净利润(净亏损以“-”
                               50,992,911.42      138,849,267.63      400,301,315.62     271,257,797.78
号填列)
  归属于母公司所有者的净
                               45,500,978.42      138,849,267.63      383,528,008.72     271,257,797.78
利润
  少数股东损益                  5,491,933.00                           16,773,306.90
六、其他综合收益的税后净



                                                15 / 21
                                        2015 年第三季度报告



  归属母公司所有者的其他
综合收益的税后净额
      (一)以后不能重分类
进损益的其他综合收益
        1.重新计量设定受益
计划净负债或净资产的变动
        2.权益法下在被投资
单位不能重分类进损益的其
他综合收益中享有的份额
      (二)以后将重分类进
损益的其他综合收益
        1.权益法下在被投资
单位以后将重分类进损益的
其他综合收益中享有的份额
        2.可供出售金融资产
公允价值变动损益
        3.持有至到期投资重
分类为可供出售金融资产损

        4.现金流量套期损益
的有效部分
        5.外币财务报表折算
差额
        6.其他
  归属于少数股东的其他综
合收益的税后净额
七、综合收益总额              50,992,911.42     138,849,267.63    400,301,315.62     271,257,797.78
  归属于母公司所有者的综
                              45,500,978.42     138,849,267.63    383,528,008.72     271,257,797.78
合收益总额
  归属于少数股东的综合收
                               5,491,933.00                        16,773,306.90
益总额
八、每股收益:
  (一)基本每股收益(元/
                                       0.01               0.05              0.12              0.09
股)
  (二)稀释每股收益(元/
                                       0.01               0.05              0.12              0.09
股)


法定代表人:孟庆山           主管会计工作负责人:李勇刚          会计机构负责人:王爱玲




                                              16 / 21
                                              2015 年第三季度报告



                                     母公司利润表
                                    2015 年 1—9 月
编制单位:梅花生物科技集团股份有限公司
                                                                单位:元    币种:人民币     审计类型:未经审计
                                                                           年初至报告期期      上年年初至报告
                                   本期金额            上期金额
             项目                                                              末金额            期期末金额
                                   (7-9 月)          (7-9 月)
                                                                             (1-9 月)           (1-9 月)
一、营业收入                    1,795,857,195.63   1,540,204,773.87      5,767,368,670.79     4,404,889,574.15
     减:营业成本               1,648,366,584.30   1,351,256,455.32      5,349,805,579.13     3,950,657,692.17
         营业税金及附加              510,791.88        1,423,781.18           6,125,245.12        3,770,422.08
         销售费用                121,153,206.83       93,312,549.47         379,735,749.50      272,312,453.13
         管理费用                 32,161,886.31       26,620,371.84          87,407,309.49       73,940,388.19
         财务费用                    310,553.03       -7,187,624.90          -2,718,379.73       -2,490,313.67
         资产减值损失                                                        -5,395,544.02        1,117,626.22
     加:公允价值变动收益(损
失以“-”号填列)
         投资收益(损失以
                                   2,186,136.62       -1,179,771.30          24,597,280.90        3,450,769.99
“-”号填列)
         其中:对联营企业和
                                   1,238,022.59       -1,614,502.54          -2,782,380.25         -957,300.88
合营企业的投资收益
二、营业利润(亏损以“-”
                                  -4,459,690.10       73,599,469.66         -22,994,007.80      109,032,076.02
号填列)
     加:营业外收入                3,357,843.33        9,773,776.73           5,412,284.57       13,748,928.62
         其中:非流动资产处
                                                                                  9,932.63             8,439.65
置利得
     减:营业外支出                1,019,471.84               5,000.00        2,101,138.07          105,362.37
         其中:非流动资产处
                                        2,977.32                                  3,483.09             1,238.33
置损失
三、利润总额(亏损总额以
                                  -2,121,318.61       83,368,246.39         -19,682,861.30      122,675,642.27
“-”号填列)
      减:所得税费用                                                            809,723.53
四、净利润(净亏损以“-”
                                  -2,121,318.61       83,368,246.39         -20,492,584.83      122,675,642.27
号填列)
五、其他综合收益的税后净

     (一)以后不能重分类进
损益的其他综合收益
       1.重新计量设定受益计
划净负债或净资产的变动
      2.权益法下在被投资单
位不能重分类进损益的其他
综合收益中享有的份额
     (二)以后将重分类进损

                                                    17 / 21
                                           2015 年第三季度报告



益的其他综合收益
       1.权益法下在被投资单
位以后将重分类进损益的其
他综合收益中享有的份额
       2.可供出售金融资产公
允价值变动损益
       3.持有至到期投资重分
类为可供出售金融资产损益
       4.现金流量套期损益的
有效部分
       5.外币财务报表折算差

       6.其他
六、综合收益总额                 -2,121,318.61      83,368,246.39        -20,492,584.83      122,675,642.27
七、每股收益:
     (一)基本每股收益(元
/股)
     (二)稀释每股收益(元
/股)


法定代表人:孟庆山            主管会计工作负责人:李勇刚           会计机构负责人:王爱玲




                                    合并现金流量表
                                    2015 年 1—9 月
编制单位:梅花生物科技集团股份有限公司
                                                              单位:元   币种:人民币     审计类型:未经审计
                     项目                          年初至报告期期末金额         上年年初至报告期期末金额
                                                           (1-9 月)                     (1-9 月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                              9,009,691,769.15                6,548,725,197.27
  客户存款和同业存放款项净增加额
  向中央银行借款净增加额
  向其他金融机构拆入资金净增加额
  收到原保险合同保费取得的现金
  收到再保险业务现金净额
  保户储金及投资款净增加额
  处置以公允价值计量且其变动计入当期损益
的金融资产净增加额
  收取利息、手续费及佣金的现金
  拆入资金净增加额
  回购业务资金净增加额
  收到的税费返还                                               64,689,434.80                   28,436,696.23

                                                 18 / 21
                                       2015 年第三季度报告



  收到其他与经营活动有关的现金                             97,127,383.70     146,735,807.26
    经营活动现金流入小计                                9,171,508,587.65   6,723,897,700.76
  购买商品、接受劳务支付的现金                          4,682,533,574.19   4,836,222,058.28
  客户贷款及垫款净增加额
  存放中央银行和同业款项净增加额
  支付原保险合同赔付款项的现金
  支付利息、手续费及佣金的现金
  支付保单红利的现金
  支付给职工以及为职工支付的现金                          584,513,621.70     446,264,801.81
  支付的各项税费                                          430,052,100.55     149,305,618.18
  支付其他与经营活动有关的现金                            911,598,081.33     740,669,031.86
    经营活动现金流出小计                                6,608,697,377.77   6,172,461,510.13
      经营活动产生的现金流量净额                        2,562,811,209.88     551,436,190.63
二、投资活动产生的现金流量:
  收回投资收到的现金
  取得投资收益收到的现金                                   31,268,658.82       4,180,886.60
  处置固定资产、无形资产和其他长期资产收回                    681,284.00      17,810,147.42
的现金净额
  处置子公司及其他营业单位收到的现金净额                   20,000,000.00
  收到其他与投资活动有关的现金                            200,000,000.00
    投资活动现金流入小计                                  251,949,942.82      21,991,034.02
  购建固定资产、无形资产和其他长期资产支付                354,559,882.85     306,988,088.05
的现金
  投资支付的现金                                          199,633,858.79     378,799,948.46
  质押贷款净增加额
  取得子公司及其他营业单位支付的现金净额
  支付其他与投资活动有关的现金
    投资活动现金流出小计                                  554,193,741.64     685,788,036.51
      投资活动产生的现金流量净额                         -302,243,798.82    -663,797,002.49
三、筹资活动产生的现金流量:
  吸收投资收到的现金                                       63,800,000.00
  其中:子公司吸收少数股东投资收到的现金                   63,800,000.00
  取得借款收到的现金                                    6,458,167,832.48   5,033,597,907.68
  发行债券收到的现金                                    1,500,000,000.00   2,000,000,000.00
  收到其他与筹资活动有关的现金                            379,864,452.87     102,106,856.66
    筹资活动现金流入小计                                8,401,832,285.35   7,135,704,764.34
  偿还债务支付的现金                                   10,092,821,017.95   6,254,966,481.68
  分配股利、利润或偿付利息支付的现金                      668,629,808.39     604,403,250.55
  其中:子公司支付给少数股东的股利、利润
  支付其他与筹资活动有关的现金                            320,616,612.57       8,886,468.00
    筹资活动现金流出小计                               11,082,067,438.91   6,868,256,200.23
      筹资活动产生的现金流量净额                       -2,680,235,153.56     267,448,564.11

                                             19 / 21
                                         2015 年第三季度报告



四、汇率变动对现金及现金等价物的影响                         36,647,403.22                  12,818,280.70
五、现金及现金等价物净增加额                               -383,020,339.28                 167,906,032.95
  加:期初现金及现金等价物余额                              559,553,015.97                 557,110,850.67
六、期末现金及现金等价物余额                                176,532,676.69                 725,016,883.62
法定代表人:孟庆山          主管会计工作负责人:李勇刚          会计机构负责人:王爱玲




                                  母公司现金流量表
                                    2015 年 1—9 月
编制单位:梅花生物科技集团股份有限公司
                                                            单位:元   币种:人民币   审计类型:未经审计
                     项目                        年初至报告期期末金额         上年年初至报告期期末金额
                                                         (1-9 月)                   (1-9 月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                            5,749,454,966.95               3,901,454,908.64
  收到的税费返还
  收到其他与经营活动有关的现金                            5,190,246,304.48               4,100,214,229.69
    经营活动现金流入小计                                 10,939,701,271.43               8,001,669,138.33
  购买商品、接受劳务支付的现金                            5,444,871,967.60               2,614,523,074.67
  支付给职工以及为职工支付的现金                             45,084,856.21                  32,668,759.25
  支付的各项税费                                             90,091,256.17                  31,911,639.66
  支付其他与经营活动有关的现金                            4,312,142,786.61               6,149,031,095.71
    经营活动现金流出小计                                  9,892,190,866.59               8,828,134,569.29
  经营活动产生的现金流量净额                              1,047,510,404.84                -826,465,430.96
二、投资活动产生的现金流量:
  收回投资收到的现金
  取得投资收益收到的现金                                    327,379,661.15                   1,085,010.54
  处置固定资产、无形资产和其他长期资产收回                        20,000.00                 17,227,762.81
的现金净额
  处置子公司及其他营业单位收到的现金净额
  收到其他与投资活动有关的现金                              200,000,000.00
    投资活动现金流入小计                                    527,399,661.15                  18,312,773.35
  购建固定资产、无形资产和其他长期资产支付                   32,281,071.00                   3,229,832.00
的现金
  投资支付的现金                                            117,700,000.00                 296,771,254.58
  取得子公司及其他营业单位支付的现金净额
  支付其他与投资活动有关的现金
    投资活动现金流出小计                                    149,981,071.00                 300,001,086.58
      投资活动产生的现金流量净额                            377,418,590.15                -281,688,313.23
三、筹资活动产生的现金流量:
  吸收投资收到的现金
  取得借款收到的现金                                      5,716,930,872.35            3,757,369,182.68


                                               20 / 21
                                       2015 年第三季度报告



  收到其他与筹资活动有关的现金                           5,686,000,000.00           2,831,000,000.00
    筹资活动现金流入小计                               11,402,930,872.35            6,588,369,182.68
  偿还债务支付的现金                                     6,581,930,872.35           2,697,369,182.68
  分配股利、利润或偿付利息支付的现金                       584,257,402.97             486,680,875.77
  支付其他与筹资活动有关的现金                           5,679,105,885.00           2,243,730,317.68
    筹资活动现金流出小计                               12,845,294,160.32            5,427,780,376.13
      筹资活动产生的现金流量净额                       -1,442,363,287.97            1,160,588,806.55
四、汇率变动对现金及现金等价物的影响                            91,904.20                      0.01
五、现金及现金等价物净增加额                               -17,342,388.78              52,435,062.37
  加:期初现金及现金等价物余额                              42,198,920.79             159,206,324.10
六、期末现金及现金等价物余额                                24,856,532.01             211,641,386.47


法定代表人:孟庆山          主管会计工作负责人:李勇刚            会计机构负责人:王爱玲




4.2 审计报告
□适用 √不适用




                                             21 / 21
数据加载中...
prevnext
手机查看股票